Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Large Drop in Short Interest

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 5,030,000 shares, a decline of 6.0% from the January 15th total of 5,350,000 shares. Currently, 9.1% of the shares of the company are sold short. Based on an average daily volume of 882,500 shares, the days-to-cover ratio is currently 5.7 days.

Wall Street Analysts Forecast Growth

AGIO has been the subject of a number of research reports. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank lifted their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Royal Bank of Canada raised their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $34.02 on Thursday. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 3.00 and a beta of 0.88. Agios Pharmaceuticals has a 1 year low of $26.19 and a 1 year high of $62.58. The stock’s fifty day moving average is $34.45 and its two-hundred day moving average is $43.14.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, analysts predict that Agios Pharmaceuticals will post -6.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 4.93% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at about $33,000. GF Fund Management CO. LTD. bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at about $39,000. Wingate Wealth Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at about $53,000. Sterling Capital Management LLC raised its stake in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.